SYDNEY, Australia, 23 October 2019: Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the company developing a new class of antibiotics, today published a white paper providing pre-clinical and experimental data on its new synthetic antibiotics and outlining the market need, its anticipated market positioning and development strategy.
The paper titled “How Synthetic Antibiotic Development Can Change the Antibiotic Treatment Model" has been distributed ahead of the World Anti-Microbial Resistance Congress to be held on Thursday 7 to Friday 8 November in Washington D.C, where Recce Chairman Dr. John Prendergast will give the Opening R&D Address.
A copy of the paper can be downloaded here.
The paper highlights how the need for new antibiotics has never been greater as resistance has developed to most currently approved antibiotics. It examines the significant potential of Recce’s promising synthetic antibiotic pipeline and potential role helping turn back the rising tide of antibiotic resistance globally. It presents data to support its potential as a life-saving antibiotic therapy, in particular for its lead application in sepsis.
A copy of Dr. John Prendergast’s presentation will be released to the ASX immediately prior to the conference in November.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a New Class of Synthetic Antibiotics with Broad Spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Recce antibiotics are unique – their potency does not diminish even with repeated use, which is a common failure associated with existing antibiotic use and the resulting emergence of resistant superbugs. Patented lead candidate RECCE® 327 wholly owned and manufactured in Australia, has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.
For more information please visit www.recce.com.au
Issued for and on behalf of Recce by Instinctif Partners.
For more information please contact: Recce@instinctif.com